Basel (CH) 18 April 2018 – Lonza Consumer Health and Nutrition is bringing new innovation through "function and form" to Vitafoods Europe 2018 via its latest ingredients, delivery systems and finished product formulations for the nutraceuticals industry. Following Lonza's recent acquisition of Capsugel, Lonza Consumer Health and Nutrition is combining its science-backed ingredients with cutting-edge dosage forms. At Booth G10 at Vitafoods, Lonza will present its ready-to-market concepts for the healthy aging, probiotics and active sports nutrition markets.
Lonza Consumer Health and Nutrition will launch its patented UC-II® joint health ingredient to the European market at Vitafoods. Backed by multiple clinical studies, the high-quality undenatured type II collagen product has been shown to support optimal joint health at low dosages by improving comfort, mobility and flexibility.  Visitors to the booth can discover a range of new, finished product concepts containing UC-II® ingredient.
On 16 May at 3 p.m. at the Ingredients Theatre, Jim Lugo, Chief Scientific Officer for Lonza Consumer Health and Nutrition, will further explore the ingredient’s benefits in a presentation titled: “UC-II® Undenatured Type II Collagen: Healthy Joints Start Here.” Additional ingredient highlights for the healthy-aging market will include Lonza's science-backed ResistAid® ingredient.
In addition to healthy aging, active nutrition is another emerging application for joint health, for which the company will demonstrate its latest combination products featuring Carnipure® ingredient, a high-quality grade of L-Carnitine. A well-established ingredient in the market, scientific studies have shown Carnipure® L-Carnitine to be beneficial for sports recovery, helping to reduce tissue damage and muscle soreness.
New formulations at Vitafoods Europe 2018 will pair Carnipure® ingredient with Capsugel’s cutting-edge Licaps® liquid-filled capsules and will include probiotics combinations for exercise and weight-management benefits, as well as a concept with vitamin B12 and choline to aid recovery and treat fatigue.
The company will also demonstrate its Lipid Multi-Particulate (LMP) technology, designed to improve the performance of nutritional actives. Visitors will be invited to find out more about LMP technology and try the Branched Chain Amino Acids (BCAAs) caffeine-drink concept at the company’s on-booth bar.
On Tuesday, 15 May, at 2.20 p.m. at the Sports Nutrition Zone Theatre, Dominik Mattern, Director Business Development at Lonza Consumer Health and Nutrition, will explore the ingredient’s active and sports nutrition applications when he delivers a seminar titled: “Sports and Active Nutrition Innovation through Function and Form”.
Experts will also be available to provide further information on the company’s leading dosage forms, including Capsugel’s DUOCAP® capsule-in-capsule technology. Various DUOCAP® probiotic capsule combinations to assure formulation stability and acid resistance will be presented for emerging applications beyond digestive health, including immunity, beauty and cardiovascular.
Lonza Consumer Health and Nutrition will further highlight its clean label capabilities through its new, innovative natural food-colored Vcaps® Plus Spirulina capsules. Considered the next generation of vegetarian-food colored capsules, the solution is now available in new colors and has been designed to support the development of true clean label solutions.
“Across the nutraceuticals industry, demand is increasing for ingredients and for encapsulation technologies that not only deliver high-quality results, but also improve speed-to-market and allow product line extension as they meet consumer needs and preferences,” said Beth Tormey, Vice President, Head of Business Unit, Consumer Health and Nutrition, Lonza.
"Our integrated solutions – from ingredient sourcing and formulation development to industry-leading capsule and encapsulation technologies and dosage capabilities – mean we can support manufacturers in doing just that," she added. "At Vitafoods Europe, manufacturers can explore our range of science-backed ingredients, advanced encapsulation technologies and finished product concepts, which will enable them to stay ahead of ever-changing trends and industry standards.”
More information about Lonza Consumer Health and Nutrition is available at Booth G10 or www.capsugel.com.
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment.
Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.
Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com.
Lonza Contact Details
Dirk Oehlers, Head Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540
Dominik Werner, Head Corporate Communications
Lonza Group Ltd
Tel +41 61 316 8798
Constance Ward, Head External Communications
Lonza Group Ltd
Tel +41 61 316 8840
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.
 Lugo JP, et al. "Efficacy and tolerability of an undenatured type ll collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study." Nutr J. 2016;15:14
 Crowley DC, et al. "Safety and efficacy of undenatured type ll collagen in the treatment of osteoarthritis of the knee: a clinical trial." Int J Med Sci. 2009;6:312-321.
 Walter P, et al. “L-Carnitine, a ‘Vitamin-Like Substance’ for Functional Food. Proceedings of the Symposium on L-Carnitine, April 28 to May 1, 2000, Zermatt, Switzerland”, Ann Nutr Metab 2000;44:75–96